Fosfomycin suppresses RS-virus-induced Streptococcus pneumoniae and Haemophilus influenzae adhesion to respiratory epithelial cells via the platelet-activating factor receptor.

FEMS Microbiology Letters
Shin-ichi YokotaNobuhiro Fujii

Abstract

Human respiratory syncytial virus (RSV) sometimes causes acute and severe lower respiratory tract illness in infants and young children. The platelet-activating factor (PAF) receptor, which is a receptor for Streptococcus pneumoniae and Haemophilus influenzae, is upregulated by RSV infection in the pulmonary epithelial cell line A549. Fosfomycin, an antimicrobial agent, significantly suppressed PAF receptor induction by RSV infection at the mRNA and cell surface expression levels. Fosfomycin also suppressed RSV-induced adhesion of fluorescence-labeled S. pneumoniae and H. influenzae cells, as determined by flow cytometry and fluorescence microscopy. The RSV-induced bacterial adhesion was suggested to be host-PAF-receptor and bacterial-phosphocholine mediated. Fosfomycin, which has been shown to exhibit antimicrobial and immunomodulatory activities, was found here to suppress adhesion by disease-causing bacteria. Thus, fosfomycin might prevent secondary bacterial infection during RSV infection.

References

Sep 1, 1981·Antimicrobial Agents and Chemotherapy·M GotoH Yamashina
Dec 1, 1993·Antimicrobial Agents and Chemotherapy·K MorikawaM Sawada
Feb 1, 1993·Antimicrobial Agents and Chemotherapy·K MorikawaS Morikawa
Jun 1, 1996·Antimicrobial Agents and Chemotherapy·K MorikawaS Morikawa
Jan 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P E KimC E Wright
Feb 1, 1997·Antimicrobial Agents and Chemotherapy·T MatsumotoK Yamaguchi
Jan 1, 1996·Advances in Experimental Medicine and Biology·D R CundellN P Gerard
Jan 1, 1997·Advances in Experimental Medicine and Biology·T Shimizu, H Mutoh
Apr 29, 1998·Pediatrics·M A AndradeE R Wald
Jan 7, 1999·International Journal of Immunopharmacology·S IshizakaS Saito
Feb 27, 1999·Antimicrobial Agents and Chemotherapy·T MatsumotoK Yamaguchi
Nov 27, 1999·FEMS Immunology and Medical Microbiology·J M HamentT F Wolfs
Oct 31, 2000·The Pediatric Infectious Disease Journal·T Chonmaitree, T Heikkinen
Apr 4, 2003·International Journal of Antimicrobial Agents·K MorikawaS Morikawa
Jun 7, 2003·International Journal of Antimicrobial Agents·Yasuto YoneshimaSusumu Furukawa
Dec 16, 2003·The Journal of Infectious Diseases·Satoshi IshizukaHidetada Sasaki
Sep 16, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Shin-ichi YokotaNobuhiro Fujii
Feb 17, 2006·Journal of Medical Virology·Tamaki OkabayashiNobuhiro Fujii
Jul 16, 2008·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yasuo OhkoshiNobuhiro Fujii
Apr 17, 2009·Clinical and Vaccine Immunology : CVI·Tamaki OkabayashiNobuhiro Fujii
Apr 28, 2009·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Stefan HajduElisabeth Presterl
Aug 19, 2009·Antimicrobial Agents and Chemotherapy·Sofia MarakiMatthew E Falagas

❮ Previous
Next ❯

Citations

Jan 18, 2013·PLoS Pathogens·Astrid A T M BoschDebby Bogaert
Apr 2, 2014·Respiratory Medicine·Reetika SuriJonathan Grigg
Dec 3, 2016·The Journal of General Virology·Carla BellinghausenFrank R M Stassen
Mar 11, 2016·Clinical Microbiology Reviews·Matthew E FalagasKonstantinos Z Vardakas

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
fluorescence microscopy

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.